Scarica l'app Stockscreener
0.1399
5.27%
0.007
Pre-mercato:
.14
0.0001
+0.07%
Precedente Chiudi:
$0.1329
Aprire:
$0.1346
Volume 24 ore:
2.32M
Relative Volume:
2.37
Capitalizzazione di mercato:
$5.01M
Reddito:
$7.10M
Utile/perdita netta:
$-39.43M
Rapporto P/E:
-0.1488
EPS:
-0.94
Flusso di cassa netto:
$-46.50M
1 W Prestazione:
+17.86%
1M Prestazione:
-57.59%
6M Prestazione:
-76.09%
1 anno Prestazione:
-80.07%
Intervallo 1D:
$0.128
$0.14
Intervallo di 1 settimana:
$0.1151
$0.14
Portata 52W:
$0.11
$0.87
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Confronta SPRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.1399 | 5.01M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Citizens JMP maintains Market Perform on Spruce Biosciences By Investing.com - Investing.com Nigeria
Citizens JMP maintains Market Perform on Spruce Biosciences - Investing.com
The Potential Rise in the Price of Spruce Biosciences Inc (SPRB) following insiders activity - knoxdaily.com
TD Cowen reiterates NextDecade Corporation (NEXT) stock to a Buy - knoxdaily.com
Q1 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $2.17 Consensus Target Price from Analysts - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript - Insider Monkey
Spruce Biosciences Inc (NASDAQ: SPRB) Slashes -6.82%: What Could Be On The Way Going Forward? - stocksregister.com
Spruce Bio sows the seeds of its new future - Pharmaphorum
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Spruce Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RBC Cuts Price Target on Spruce Biosciences to $0.50 From $1.50, Keeps Sector Perform, Speculative Risk - marketscreener.com
Spruce Biosciences Announces New Corporate Strategy and Acquisit - GuruFocus
SPRB stock touches 52-week low at $0.18 amid market challenges By Investing.com - Investing.com South Africa
Spruce Biosciences plans BLA for rare disease therapy By Investing.com - Investing.com South Africa
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
SPRB stock touches 52-week low at $0.18 amid market challenges - Investing.com Canada
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Spruce Biosciences (SPRB) Acquires New Therapy for Rare Disease Treatment | SPRB Stock News - GuruFocus
Spruce Biosciences plans BLA for rare disease therapy - Investing.com Australia
SPRUCE BIOSCIENCES, INC. SEC 10-K Report - TradingView
Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa - MarketScreener
Major Rare Disease Breakthrough: Spruce Bio Secures Promising Treatment for Fatal Childhood Disease - Stock Titan
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
SPRB stock touches 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa
SPRB stock touches 52-week low at $0.26 amid market challenges - Investing.com India
Congenital Adrenal Hyperplasia Treatment Market: Key Trends, - openPR.com
Spruce Biosciences reports delayed annual filing By Investing.com - Investing.com Australia
Spruce Biosciences reports delayed annual filing - Investing.com
Spruce Biosciences Delays Annual Report Filing - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Spruce Biosciences stock hits 52-week low at $0.32 - Investing.com
In-Depth Analysis Of The Global Congenital Adrenal Hyperplasia Market: Key Drivers, Trends, Growth Opportun... - WhaTech
Spruce Biosciences stock hits 52-week low at $0.32 By Investing.com - Investing.com Canada
SPRUCE BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $2.38 - Defense World
SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com India
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spruce Biosciences Inc Azioni (SPRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Charlton Ralph William III | CHIEF MEDICAL OFFICER |
Dec 10 '24 |
Option Exercise |
0.00 |
106,400 |
0 |
161,773 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 16 '24 |
Option Exercise |
0.00 |
75,750 |
0 |
363,841 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '24 |
Option Exercise |
0.00 |
154,000 |
0 |
356,776 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Option Exercise |
0.00 |
200,700 |
0 |
506,796 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '24 |
Option Exercise |
0.00 |
358,800 |
0 |
466,121 |
2.04%
2.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):